OPK - OPKO Health Inc Stock Price, Fair Value and News

1.32USD+0.02 (+1.54%)Market Closed

Market Summary

USD1.32+0.02

Market Closed

1.54%

OPK Alerts

Big fall in Revenue (Y/Y)

Big fall in earnings (Y/Y)
Losses in recent quarter

OPK Stock Price

View Fullscreen

OPK RSI Chart

OPK Valuation

Market Cap

920.0M

Price/Earnings (Trailing)

-3.64

Price/Sales (Trailing)

1.15

EV/EBITDA

-6.38

Price/Free Cashflow

-22.38

OPK Price/Sales (Trailing)

OPK Profitability

EBT Margin

-31.33%

Return on Equity

-20.15%

Return on Assets

-12.79%

Free Cashflow Yield

-4.47%

OPK Fundamentals

OPK Revenue

Revenue (TTM)

799.6M

Rev. Growth (Yr)

-26.89%

Rev. Growth (Qtr)

-4.52%

OPK Earnings

Earnings (TTM)

-252.4M

Earnings Growth (Yr)

-348%

Earnings Growth (Qtr)

-23.09%

Breaking Down OPK Revenue

Last 7 days

3.1%

Last 30 days

5.6%

Last 90 days

30.7%

Trailing 12 Months

-16.5%

How does OPK drawdown profile look like?

OPK Financial Health

Current Ratio

1.91

Debt/Equity

Debt/Cashflow

-10.19

OPK Investor Care

Buy Backs (1Y)

9.79%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	799.6M	0	0	0
2023	912.6M	868.1M	866.9M	863.5M
2022	1.6B	1.4B	1.2B	1.0B
2021	1.8B	1.9B	1.9B	1.8B
2020	891.0M	965.8M	1.2B	1.4B
2019	957.8M	920.5M	899.4M	901.9M
2018	954.5M	925.6M	929.4M	990.3M
2017	1.1B	1.1B	1.1B	966.0M
2016	730.6M	1.0B	1.1B	1.1B
2015	98.9M	117.8M	241.1M	491.7M
2014	87.4M	87.2M	86.3M	91.1M
2013	69.6M	83.3M	92.1M	96.5M
2012	29.8M	31.6M	36.6M	47.0M
2011	32.3M	33.3M	34.4M	28.0M
2010	0	12.4M	20.5M	28.5M
2009	0	0	0	4.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of OPKO Health Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	frost phillip md et al	bought	437,100	0.8742	500,000	ceo & chairman
Mar 14, 2024	frost phillip md et al	bought	444,300	0.8886	500,000	ceo & chairman
Mar 13, 2024	frost phillip md et al	bought	463,750	0.9275	500,000	ceo & chairman
Mar 12, 2024	frost phillip md et al	bought	559,380	0.9323	600,000	ceo & chairman
Feb 28, 2024	frost phillip md et al	bought	496,150	0.9923	500,000	ceo & chairman
Feb 21, 2024	frost phillip md et al	bought	991,700	0.9917	1,000,000	ceo & chairman
Feb 07, 2024	frost phillip md et al	bought	1,462,800	0.9752	1,500,000	ceo & chairman
Jan 29, 2024	krasno richard m	bought	29,838	0.9946	30,000	-
Jan 19, 2024	frost phillip md et al	bought	488,650	0.9773	500,000	ceo & chairman
Jan 18, 2024	frost phillip md et al	bought	386,200	0.9655	400,000	ceo & chairman

Which funds bought or sold OPK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Kozak & Associates, Inc.	sold off	-	-	-	-%
May 16, 2024	Tidal Investments LLC	new	-	238,728	238,728	-%
May 16, 2024	FSA Wealth Management LLC	unchanged	-	-1,260	4,740	-%
May 16, 2024	AWM Investment Company, Inc.	added	18.18	-101,000	1,560,000	0.20%
May 16, 2024	COMERICA BANK	added	125	47,600	108,000	-%
May 16, 2024	JANE STREET GROUP, LLC	added	269	1,048,990	1,589,790	-%
May 16, 2024	KLCM Advisors, Inc.	unchanged	-	-3,100	12,000	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.00	-164,620	507,212	-%
May 15, 2024	Sassicaia Capital Advisers LLC	new	-	19,200	19,200	0.08%
May 15, 2024	JANUS HENDERSON GROUP PLC	added	0.01	-61,508	252,219	-%

Are Funds Buying or Selling OPK?

Are funds buying OPK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OPK

No. of Funds

Unveiling OPKO Health Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.14%	39,751,293	SC 13G/A
Jan 24, 2024	frost phillip md et al	-	8	SC 13D/A
Jan 24, 2024	hsiao jane ph d	-	11	SC 13D/A
Jan 22, 2024	frost phillip md et al	-	8	SC 13D/A
Feb 21, 2023	frost phillip md et al	27.2%	213,891,935	SC 13D/A
Feb 09, 2023	vanguard group inc	5.32%	41,120,494	SC 13G/A
Aug 19, 2022	frost phillip md et al	26.0%	202,156,694	SC 13D/A
Aug 19, 2022	hsiao jane ph d	0.7%	5,127,404	SC 13D/A
Jun 29, 2022	zerhouni elias a.	2.9%	19,867,114	SC 13D
Jun 29, 2022	nabel gary j.	2.9%	20,012,985	SC 13D

Recent SEC filings of OPKO Health Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	8-K	Current Report

Peers (Alternatives to OPKO Health Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	196.9B	23.7B	11.04%	17.40%	44.73	8.29	-8.94%	-35.91%
A	45.2B	6.7B	14.64%	19.44%	36.57	6.71	-2.81%	-6.58%
IDXX	44.9B	3.7B	13.71%	10.52%	51.83	12.06	8.57%	23.94%
DGX	16.0B	9.3B	13.66%	10.24%	18.95	1.73	-3.29%	6.68%
NTRA	13.1B	1.2B	17.80%	114.36%	-35.76	10.81	39.26%	33.08%
MEDP	12.2B	2.0B	2.71%	87.82%	38.94	6.2	25.57%	21.62%
CRL	11.4B	4.1B	-3.66%	11.24%	26.02	2.78	0.49%	-11.59%
EXAS	9.3B	2.5B	-20.33%	-38.03%	-38.69	3.67	15.21%	53.51%
MID-CAP
GH	3.1B	603.7M	54.73%	-14.09%	-6.73	5.14	25.21%	30.68%
NEOG	2.9B	929.2M	11.70%	-18.80%	1.9K	3.16	28.93%	111.61%
SMALL-CAP
CDNA	808.3M	275.1M	87.44%	103.94%	-4.41	2.94	-13.93%	-126.97%
ACRS	84.8M	31.1M	-3.25%	-85.34%	-1.1	2.73	0.95%	19.75%
AWH	33.0M	9.2M	-24.07%	-37.65%	-2.24	3.6	11.85%	45.80%
APDN	2.5M	5.5M	-62.31%	120.18%	-0.2	0.45	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

OPKO Health Inc News

Latest updates

OPKO Health Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-4.5%	173,686,000	181,905,000	178,595,000	265,418,000	237,577,000	185,340,000	179,744,000	309,893,000	329,219,000	401,332,000	385,813,000	442,408,000	545,165,000	494,676,000	428,064,000	301,207,000	211,466,000	224,344,000	228,772,000	226,368,000	222,451,000
Operating Expenses	-2.3%	245,158,000	250,949,000	243,002,000	258,393,000	268,171,000	240,610,000	267,564,000	320,632,000	401,643,000	464,416,000	347,987,000	436,837,000	506,728,000	445,318,000	406,125,000	274,028,000	252,228,000	336,807,000	267,783,000	273,628,000	297,769,000
S&GA Expenses	-3.7%	70,167,000	72,883,000	72,240,000	79,794,000	75,642,000	73,997,000	79,674,000	101,464,000	117,537,000	138,214,500	105,120,000	113,236,000	112,286,000	101,823,500	99,897,000	77,721,000	76,132,000	79,130,000	80,542,000	88,475,000	95,158,000
R&D Expenses	13.1%	21,937,000	19,394,000	19,435,000	18,159,000	32,605,000	19,528,500	18,792,000	17,254,000	18,312,000	21,007,000	18,306,000	18,222,000	19,315,000	17,454,500	18,493,000	17,608,000	21,760,000	23,038,000	30,017,000	28,286,000	36,529,000
EBITDA Margin	-119.4%	-0.17	-0.08	-0.11	-0.16	-0.23	-0.27	-0.19	-0.06	-0.01	0.05	0.10	0.09	-	-	-	-	-	-	-	-	-
Interest Expenses	-3.4%	3,125,000	3,234,000	3,384,000	3,277,000	3,830,000	2,923,000	3,017,000	3,075,000	3,420,000	10,494,000	3,503,000	194,000	4,689,000	251,000	5,079,000	566,000	5,012,000	789,000	5,673,000	4,900,000	511,000
Income Taxes	77.6%	-1,350,000	-6,019,000	6,075,000	3,148,000	1,233,000	-16,975,500	-40,327,000	15,070,000	-21,266,000	7,495,500	2,680,000	4,754,000	560,000	13,596,000	-3,178,000	6,028,000	1,171,000	3,424,000	1,769,000	1,084,000	783,000
Earnings Before Taxes	-14.7%	-83,183,000	-72,494,000	-78,378,000	-16,450,000	-16,997,000	-102,183,000	-126,375,000	-86,312,000	-76,650,000	-65,812,500	31,472,000	-11,365,000	31,681,000	45,941,000	20,649,000	39,920,000	-57,827,000	-108,445,000	-59,944,000	-58,451,000	-78,125,000
EBT Margin	-46.8%	-0.31	-0.21	-0.25	-0.30	-0.36	-0.39	-0.29	-0.14	-0.08	-0.01	0.05	0.05	-	-	-	-	-	-	-	-	-
Net Income	-23.1%	-81,836,000	-66,483,000	-84,473,000	-19,640,000	-18,267,000	-85,231,000	-86,091,000	-101,650,000	-55,433,000	-73,775,000	28,739,000	-16,186,000	31,078,000	32,298,000	23,717,000	33,703,000	-59,132,000	-112,350,000	-62,007,000	-59,806,000	-80,762,000
Net Income Margin	-44.3%	-0.32	-0.22	-0.24	-0.24	-0.32	-0.33	-0.26	-0.14	-0.07	-0.02	0.04	0.04	-	-	-	-	-	-	-	-	-
Free Cashflow	7.1%	-35,566,000	-38,294,000	33,109,000	-365,000	-22,647,000	-31,620,000	-32,236,000	-11,477,000	-19,856,000	-5,643,000	33,395,000	-15,452,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.9%	1,974	2,012	2,057	2,159	2,170	2,167	2,225	2,370	2,307	2,400	2,418	2,422	2,520	2,473	2,371	2,324	2,233	2,309	2,370	2,456	2,575
Current Assets	26.4%	391	309	357	434	406	395	414	495	754	823	558	547	599	523	428	360	274	324	293	344	435
Cash Equivalents	-21.1%	76.00	96.00	139	108	111	153	181	210	102	135	149	66.00	90.00	72.00	36.00	22.00	35.00	85.00	65.00	111	207
Inventory	-9.6%	59.00	66.00	69.00	74.00	75.00	74.00	71.00	83.00	99.00	87.00	113	135	159	132	112	73.00	59.00	53.00	50.00	48.00	45.00
Net PPE	-14.9%	64.00	75.00	78.00	79.00	-	83.00	-	-	-	-	-	-	139	141	134	131	127	127	129	137	140
Goodwill	-11.3%	531	598	594	597	597	596	573	579	519	710	675	677	676	719	676	672	670	710	696	700	699
Liabilities	15.9%	721	622	612	624	618	606	596	651	692	715	652	679	823	802	748	735	684	695	728	747	813
Current Liabilities	2.1%	204	200	201	226	222	213	267	215	309	330	283	304	404	375	336	280	245	249	270	283	396
Long Term Debt	-47.8%	4.00	8.00	-	-	-	-	-	-	-	-	2.00	4.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	5.00	4.00
LT Debt, Current	-8.5%	2.00	2.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	2.00	4.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	5.00	4.00
Shareholder's Equity	-9.8%	1,253	1,389	1,445	1,535	1,552	1,562	1,629	1,719	1,615	1,685	1,766	1,743	1,697	1,672	1,624	1,588	1,549	1,615	1,642	1,709	1,763
Retained Earnings	-4.1%	-2,093	-2,011	-1,945	-1,860	-1,841	-1,822	-1,737	-1,651	-1,549	-1,511	-1,438	-1,466	-1,450	-1,481	-1,514	-1,537	-1,571	-1,511	-1,398	-1,336	-1,276
Additional Paid-In Capital	-1.4%	3,386	3,433	3,430	3,427	3,425	3,422	3,419	3,414	3,191	3,222	3,219	3,214	3,156	3,153	3,150	3,147	3,145	3,143	3,065	3,062	3,059
Accumulated Depreciation	-100.0%	-	157	-	-	-	142	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	-6.0%	707	752	752	752	752	719	750	713	660	648	647	647	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	904	-	-	-	1,061	-	-	-	1,607	-	-	-	1,362	-	-	-	867	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	7.1%	-35,566	-38,294	33,109	-365	-22,647	-31,620	-32,236	-11,477	-19,856	-5,643	33,395	-15,452	26,037	34,258	63,011	-14,423	-43,370	-46,037	-23,866	-53,631	-48,988
Share Based Compensation	-3.7%	2,590	2,690	3,200	2,800	2,700	3,193	3,400	4,300	7,617	3,671	3,822	3,460	2,647	2,123	2,740	1,586	2,451	2,393	3,428	3,122	4,457
Cashflow From Investing	-209.9%	-4,395	-1,418	-3,572	-5,491	-7,717	-7,872	-4,682	108,495	-4,903	-8,679	54,576	-8,842	-1,106	-6,744	5,501	-11,465	-5,619	-3,756	-2,191	-3,191	-4,132
Cashflow From Financing	649.5%	20,613	-3,751	2,105	3,462	-13,119	10,144	8,444	12,274	-7,891	833	-4,255	264	-7,192	8,108	-54,461	12,888	-1,611	70,644	-19,995	-39,276	163,875
Buy Backs	-	50,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OPK Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Revenues	$ 173,686	$ 237,577
Costs and expenses:
Selling, general and administrative	70,167	75,642
Research and development	21,937	32,605
Contingent consideration	0	136
Amortization of intangible assets	21,437	21,474
Total costs and expenses	245,158	268,171
Operating loss	(71,472)	(30,594)
Other income and (expense), net:
Interest income	813	1,030
Interest expense	(7,686)	(3,391)
Fair value changes of derivative instruments, net	(26,161)	(1,059)
Other income, net	21,323	17,017
Other income (expense), net	(11,711)	13,597
Loss before income taxes and investment losses	(83,183)	(16,997)
Income tax benefit (provision)	1,350	(1,233)
Net loss before investment losses	(81,833)	(18,230)
Loss from investments in investees	(3)	(37)
Net loss	$ (81,836)	$ (18,267)
Loss per share, basic and diluted:
Loss per share (in dollars per share)	$ (0.12)	$ (0.02)
Weighted average common shares outstanding, basic and diluted (in shares)	706,882,189	751,506,257
Service [Member]
Revenues:
Revenues	$ 126,890	$ 132,368
Costs and expenses:
Cost of Goods and Services Sold	109,873	114,059
Product [Member]
Revenues:
Revenues	38,047	40,383
Costs and expenses:
Cost of Goods and Services Sold	21,744	24,255
Transfer of Intellectual Property and Other [Member]
Revenues:
Revenues	$ 8,749	$ 64,826

OPK Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 75,639	$ 95,881
Accounts receivable, net	111,367	123,379
Inventory, net	59,366	65,697
Other current assets and prepaid expenses	24,652	24,519
Assets held for sale	120,279	0
Total current assets	391,303	309,476
Property, plant and equipment, net	64,165	75,429
Intangible assets, net	680,034	740,283
In-process research and development	195,000	195,000
Goodwill	530,615	598,260
Investments	40,990	16,082
Operating lease right-of-use assets	63,331	68,088
Other assets	8,578	9,080
Total assets	1,974,016	2,011,698
Current liabilities:
Accounts payable	71,157	69,677
Accrued expenses	88,772	90,086
Current maturities of operating leases	11,742	12,996
Current portion of convertible notes	170	0
Current portion of lines of credit and notes payable	22,820	27,293
Liabilities associated with assets held for sale	9,677	0
Total current liabilities	204,338	200,052
Operating lease liabilities	50,931	54,140
Long term portion of convertible notes	323,108	214,325
Deferred tax liabilities	121,635	126,773
Other long-term liabilities, principally contract liabilities, contingent consideration and lines of credit	21,196	27,189
Total long-term liabilities	516,870	422,427
Total liabilities	721,208	622,479
Equity:
Common Stock - $0.01 par value, 1,000,000,000 shares authorized; 726,791,854 and 781,936,885 shares issued at March 31, 2024 and December 31, 2023, respectively	7,269	7,820
Treasury Stock - 29,772,753, and 8,655,082 shares at March 31, 2024 and December 31, 2023, respectively	(1,791)	(1,791)
Additional paid-in capital	3,386,147	3,433,006
Accumulated other comprehensive loss	(45,195)	(38,030)
Accumulated deficit	(2,093,622)	(2,011,786)
Total shareholders’ equity	1,252,808	1,389,219
Total liabilities and equity	$ 1,974,016	$ 2,011,698

About OPKO Health Inc

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

CEO	Dr. Phillip Frost Ph.D.
WEBSITE	opko.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	4196

OPKO Health Inc Frequently Asked Questions

What is the ticker symbol for OPKO Health Inc? What does OPK stand for in stocks?

OPK is the stock ticker symbol of OPKO Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of OPKO Health Inc (OPK)?

As of Fri May 17 2024, market cap of OPKO Health Inc is 920.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OPK stock?

You can check OPK's fair value in chart for subscribers.

What is the fair value of OPK stock?

You can check OPK's fair value in chart for subscribers. The fair value of OPKO Health Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of OPKO Health Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OPK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is OPKO Health Inc a good stock to buy?

The fair value guage provides a quick view whether OPK is over valued or under valued. Whether OPKO Health Inc is cheap or expensive depends on the assumptions which impact OPKO Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OPK.

What is OPKO Health Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, OPK's PE ratio (Price to Earnings) is -3.64 and Price to Sales (PS) ratio is 1.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OPK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on OPKO Health Inc's stock?

In the past 10 years, OPKO Health Inc has provided -0.168 (multiply by 100 for percentage) rate of return.